Exhibit P1. Major therapies under trial for CEACAM5 precision tumors mid-2026.
The activity of CEACAM5 field is high, with 44 assets from different technology platforms participating, approvals now looking plausible with at least three ADCs by leaders – EMD, Pfizer and BMS – progressing steadily including the beginning of Phase 3 by EMD and other two leaders developing alternate niches. The question has shifted from which drug will get first approvals to which entity will remain in the lead during the ten years from launch and which one will cede – the answer directly impacts the valuation and returns. Study shows the choices made during clinical development will be deterministic for this.
The most heavily weighted questions are around patient enrichment, endpoint designs and in a heavily contested field are even likely to optimize SOC L1 parameters early on. This is very relevant in oncology as it offers examples of both – first-to-market products retaining leadership for years as well as later entrants displacing them. The differentiation is difficult to establish post launch as it can be costly to say the least, or the competitive intensity may lead to a loss of opportunity altogether.
Why This Window of Time Matters
In the last 12 months, CEACAM5 programs have had eleven significant phase transitions:
EMD's CEACAM5 program has advanced into Phase 3 — the most advanced asset at this stage.
KIVU-305 has entered Phase 2.
LM-24C5 has completed Phase 2 in China and is now also running Phase 2 in the United States.
EBC-129 and IBI3020 have each entered Phase 1.
IM-1335 and AKTX-102 are completing IND-enabling work, with Phase 1 entry expected shortly.
Four new CAR-T programs have initiated trials (three Phase 1/2, one Phase 1).
Each of these transitions locks in choices — patient-selection criteria, companion-diagnostic strategy, endpoint design, payload and linker selection — that become far more expensive to revisit once made. For a company still finalizing its own CEACAM5 strategy, or an investor evaluating where to place capital in this field, the number of open decisions is shrinking in real time and competition can further intensify due to underlying biology led segmentation, and dynamics, together with the current IP position.
Paths to Sustained Leadership and Actionable Steps
What did a systematic study of 187 trials reveal? CEACAM5 has been a subject of about 400 clinical trials registered globally, mostly in the USA, Japan and China. The shortlisted dataset had the latest entries where the protein is used as the therapeutic target, companion diagnostic, procedural component, or clinically relevant biomarker ignoring purely behavioural, procedural, and observational studies for the time being. Analysis was conducted in four parts:
1. Evidence: Taking each clinical trial as a node, we integrated primary scientific publications, patent literature, freedom-to-operate considerations, diagnostics, standards of care, competitive intelligence, and adjacent technologies.
2. Paths to Leadership: Analysis of the biologically segmented market and its competing platforms was conducted using game theory to assess potential interactions and strategic choices. In a fragmented market such as CEACAM5, the objective is therefore not simply to succeed first, but to establish a position that competitors find difficult to displace.
Exhibit P2. Total market and presently addressable market – Impact of Diagnostics3. Translation to Clinical Development: These findings were translated into testable scientific hypotheses — a set of relatively small but potentially high-impact changes to commonly used trial designs that could strengthen long-term competitive positioning.
4. Expansion of addressable Market: The argument for higher sensitivity and tighter variance is natural in any precision oncology strategy, Her2/Neu low and ultralow and their impact form a confirmation. Based on modeling discussed in detail in Sections 1, 3 and 9, the present trials address approximately 11% of the total available market estimated to be in the range of 800,000 annual incidence in the USA. Additional 400,000 patients can be benefitted from the treatments with the development of right diagnostics.
To be certain, prior to release of the report, the practicality of the proposed diagnostics was ascertained by real executable scientific feasibility and project plans. The proposal presented here has feasibility of development in a 9–12 month timeline toward research-use-only deployment, with a subsequent pathway toward regulatory use.
Higher Impact than Appreciated: Choices made during clinical trials regarding inclusion, exclusion, companion diagnostic strategy, endpoint design become far more expensive to revisit by the incumbent and become difficult to compete head to head by a new entrant. For a leader who starts the trials, the missed opportunity constitutes the cost, and company still finalizing its own CEACAM5 strategy, or an investor evaluating where to place capital in this field, the number of open decisions shrink as a competitor starts the trial.
This dossier is the inaugural publication applying the Simultaneous Iterative Optimization (SIO™) framework. The framework identifies the variables most likely to determine long-term enterprise value for the development problem under consideration, models those variables, assesses their relative influence, and explores the highest-impact interactions through iterative optimization. The variables differ by therapeutic area and target; the aim of the exercise is the same — to realize the highest possible value over the ten years following launch.
These dimensions are treated as interacting rather than independent variables, because a change in one can alter the strategic value of the others.
Traditional due diligence is often deeper, broader, and answers important legal, scientific, and commercial questions. This report addresses a related but different one:
How much future market position is secured by today's decisions, and how much is left open to future competition?
Answering that question well typically requires a cross-functional team: a BD or strategy lead who understands deal structure and licensing value, a clinical development lead who understands trial-design trade-offs, and a diagnostics R&D lead who understands companion-diagnostic and patient-selection strategy.
This analysis combines primary research with expert translation across business development, clinical development, and diagnostics to assess asset value, development options, diagnostic feasibility, valuation, and potential deal structures — by analyzing 187 clinical trials covering 26 named clinical-stage programs and the competitive and technological context surrounding them, and their potential interactions as they compete for a shared patient base.
The Twelve Strategic Questions
The twelve sections that follow examine the central question from complementary perspectives. Together they provide not simply a review of CEACAM5, but a working framework for evaluating long-term competitive leadership — the same framework applied to all 26 programs analyzed in this dossier.
1. How Does Target Biology Decide Clinical Development and Long-Term Strategy?
The biology that determines patient selection, and therapeutic limitations — including the substantial proportion of patients who remain outside today's development strategies, and why identical CEACAM5 expression does not imply identical treatability. Local tumor architecture, not receptor presence alone, governs whether a given construct can reach and kill CEACAM5-expressing cells — pancreatic ductal adenocarcinoma's dense stromal barrier is the clearest example, discussed in full in Section 1.
Key takeaway: Biology determines not only what can be developed, but where the next competitive white space will open — and why a single development thesis cannot be applied uniformly across tumor types.
2. What Is the Competitive Landscape, and How Can Leadership Be Designed During Clinical Development?
Current activity shows a field with multiple technology platforms, dozens of active programs, and substantial unaddressed patient population. Section 2 models whether specific development decisions can consolidate advantage and reduce future erosion.
Key takeaway: Long-term leadership is influenced as much by development strategy as by being first to market.
3. Can a Clinical Development Plan Be a Determinant of Ten-Year Leadership?
Based on analysis of 187 trials for design elements — patient enrichment, endpoint selection, regulatory strategy, strategic gaps — the dossier projects patient expansion, lifecycle planning, competitive differentiation, and program sequencing, summarized in Section 3.
Key takeaway: Clinical trials can be transformed into tools of competitive strategy without altering the underlying science.
4. What Are Terminated and Strategically Paused Programs Indicating?
Of the programs analyzed, only one — Sanofi's tusamitamab ravtansine — has been discontinued for stated adverse events (analysis supports a more complex dynamic and is listed in the report). Section 4 identifies which paused programs are positioned to re-enter development and reshape the field once regulatory hurdles are cleared.
Key takeaway: Beyond the programs actively competing, the field carries potential disruptors in strategic pause — not simply a shrinking competitive set.
5. Who Are the Key Competitors, and What Are Their Likely Next Moves?
Section 4 maps the running named programs, the five platform-technology companies positioned for opportunistic entry, and the structural forces likely to drive fragmentation or consolidation of the patient base. ADC architecture implications are in Section 5.
Key takeaway: To consolidate and lead a biologically segmented market with multiple companies developing assets, understanding competitor choices is as important as knowing every detail of one's own internal program.
6. What Is the Role and Value of Antibody Composition of Matter?
Section 6 is a research on known epitopes, patent coverage, and freedom-to-operate considerations together with a structured due-diligence framework, including a twenty-question checklist for evaluating antibody value.
Key takeaway: Current antibody IP leaves meaningful strategic white space — and that white space closes as more programs advance.
7. Are Payloads the Differentiating Feature for ADCs?
Payload selection increasingly drives efficacy, toxicity, and competitive positioning. Section 7 assesses existing intellectual property, adjacent technologies, and where future differentiation is likely to emerge, with a due-diligence checklist for evaluating payload value.
Key takeaway: Payloads are difficult to substitute once development is advanced — early choices shape competitive resilience for years. The question after selection becomes how clinical trial design can exploit the payload to its optimal value in service of long-term leadership.
8. What Is Linker Strategy, and Is It Being Exploited Fully?
Current approaches, adjacent innovation, and future opportunities are evaluated together with a practical due-diligence checklist for establishing rational valuation presented in Section 8.
Key takeaway: Linker innovation is becoming an increasingly important mechanism for protecting future franchise value.
9. Is Diagnostics an Enabler or a Limiting Factor, and How Can It Be Leveraged?
Section 9 examines how diagnostics influence patient recruitment, regulatory approval, payer acceptance, and market size, and identifies specific opportunities to expand eligible populations.
Key takeaway: Companion diagnostics represent one of the highest-return investments available for strengthening long-term franchise value.
10. Can Today's Clinical Development Steps Expedite Inclusion in First-Line Standard of Care?
Section 10 evaluates current standards of care alongside potential positioning strategies for CEACAM5-directed therapies.
Key takeaway: Regulatory approval establishes market entry; standard-of-care adoption determines commercial success — and the path between the two is set earlier than most programs are planning for.
11. What Valuation Models Maximize Investor and Investee Gains?
Alternative development scenarios are modeled in Section 11 to examine their influence on peak sales, licensing structures, and investment outcomes.
Key takeaway: Small changes in development strategy can translate into substantial differences in long-term valuation.
12. Executive Dashboards: What Do the Findings Mean in Practice?
The final Section 12 integrates the preceding analyses into practical decision frameworks for clinical development, business development and licensing, corporate strategy, and investment teams.
Key takeaway: The value of strategic intelligence lies not in accumulating information, but in improving decisions — and in this field, those decisions are being made now.
What this Study Aims to Offer
CEACAM5 has reached inflection with the EMD ADC entering Phase 3. There are about 46 drug candidates in competition and last 12 months have seen 11 phase transitions – indicating the intensity of clinical development. This study does not aim to project the probability of success or first marketing authorization. Instead, it asks two different questions – the impact of a patent estate and realistic valuation, which takes market share (and dominance) as an important assumption. The approach is simultaneous and iterative optimization – of asset value and clinical development choices. The results are choices that enhance the value of the asset. The approach offers –
For Business Development and Licensing
Pointers on placing value on patent estates. The report includes due-diligence sheets for each component of ADC, the leading moiety inside the report, which helps arriving at a realistic value, leading to different deal structures.
It also offers dynamic market size model with not only assumptions, but also the diagnostics and niche creation approaches for expansion.
For Clinical Development Teams
While the scientific and regulatory focus is uncompromised in clinical trials, the study identifies subtle but concrete changes in designs that will result in long-term leadership of the asset under development. Such translation is detailed in Sections 2 and 3 with the support of Section 9 of this report.
For Investors
CEACAM5 offers an ecosystem offering opportunities in several aspects – diagnostics, asset development, being the main ones. Strategic analysis optimizing for ROI opens up new possibilities. In case a diagnostic approach is supported, for example digital pathology proposed in Section 9, it can be developed as a platform technology. In case Multiplex IHCs are funded, the data generated will have nonlinear value and systems to capture it should be developed in parallel.
For therapeutics, asset development has all inherent risks of any clinical trial. CEACAM5 has additional risk of technology substitution as discussed in the report. An alternate possibility can be to own a part of the biology say pancreatic or lung cancers and developing various assets around that biology. This will be a much more de-risked strategy and will generate higher ROI. Details of such constructs are included in Section 2 of the report.
